OCUGEN, INC. Repayments of Other Debt
OCUGEN, INC. (OCGN) reported Repayments of Other Debt of $4.36 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfOtherDebt · last filed 2020-11-06
- OCUGEN, INC. repayments of other debt for the quarter ending 2020-09-30 was $3.22M, a 39.08% decline year-over-year.
- OCUGEN, INC. repayments of other debt for the quarter ending 2019-09-30 was $5.29M.
| Period end | Repayments of Other Debt 3 month | Repayments of Other Debt 6 month | Repayments of Other Debt 9 month |
|---|---|---|---|
| 2020-09-30 | $3.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $4.36M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $1.14M 10-Q · filed 2020-08-14 | ||
| 2019-09-30 | $5.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $5.29M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |